Jane De Lartigue

1.1k total citations · 1 hit paper
29 papers, 835 citations indexed

About

Jane De Lartigue is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jane De Lartigue has authored 29 papers receiving a total of 835 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jane De Lartigue's work include Lung Cancer Treatments and Mutations (3 papers), Biosimilars and Bioanalytical Methods (3 papers) and Reproductive Biology and Fertility (2 papers). Jane De Lartigue is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Biosimilars and Bioanalytical Methods (3 papers) and Reproductive Biology and Fertility (2 papers). Jane De Lartigue collaborates with scholars based in United Kingdom and United States. Jane De Lartigue's co-authors include Sylvie Urbé, Michael J. Clague, Hannah E.J. Polson, Sharon A. Tooze, Daniel J. Rigden, Kevan M. Shokat, Ingrid Brust‐Mascher, Jonathan M. Scholey and Jame Abraham and has published in prestigious journals such as Experimental Cell Research, Autophagy and Traffic.

In The Last Decade

Jane De Lartigue

26 papers receiving 825 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mammalian Atg18 (WIPI2) localizes to omegasome-anchored phagophores and positively regulates LC3 lipidation

2010 543 citations Hannah E.J. Polson, Jane De Lartigue et al. Autophagy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jane De Lartigue United Kingdom	8	550	339	329	159	110	29	835
Shanta Nag United States	9	705 1.3×	380 1.1×	359 1.1×	136 0.9×	114 1.0×	10	913
Zhenyuan Tang United States	10	437 0.8×	305 0.9×	309 0.9×	86 0.5×	80 0.7×	11	681
Monika Kijańska Switzerland	9	482 0.9×	312 0.9×	363 1.1×	100 0.6×	53 0.5×	10	861
Andrea Orsi Italy	15	601 1.1×	554 1.6×	756 2.3×	114 0.7×	109 1.0×	21	1.4k
Eric Bunker United States	15	524 1.0×	170 0.5×	637 1.9×	70 0.4×	86 0.8×	21	1.0k
Eri Asai Japan	8	386 0.7×	237 0.7×	375 1.1×	59 0.4×	47 0.4×	8	684
Silvia Matteoni Italy	13	360 0.7×	152 0.4×	485 1.5×	54 0.3×	82 0.7×	19	862
Xuehuo Zeng United States	9	399 0.7×	126 0.4×	320 1.0×	65 0.4×	71 0.6×	10	610
Nikit Kumar United States	13	400 0.7×	453 1.3×	614 1.9×	93 0.6×	186 1.7×	18	1.2k
Mayurbhai H. Sahani India	10	522 0.9×	143 0.4×	252 0.8×	70 0.4×	67 0.6×	10	701

Countries citing papers authored by Jane De Lartigue

Since Specialization

Citations

This map shows the geographic impact of Jane De Lartigue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane De Lartigue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane De Lartigue more than expected).

Fields of papers citing papers by Jane De Lartigue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane De Lartigue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane De Lartigue. The network helps show where Jane De Lartigue may publish in the future.

Co-authorship network of co-authors of Jane De Lartigue

This figure shows the co-authorship network connecting the top 25 collaborators of Jane De Lartigue. A scholar is included among the top collaborators of Jane De Lartigue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane De Lartigue. Jane De Lartigue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lartigue, Jane De. (2018). Trastuzumab-dkst approval adds to the biosimilar cancer drug market. The Journal of Community and Supportive Oncology. 16(2). e63–e65. 1 indexed citations

Lartigue, Jane De. (2018). Game changers in pediatric cancer. The Journal of Community and Supportive Oncology. 16(5). e210–e216. 1 indexed citations

Lartigue, Jane De. (2017). Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval. The Journal of Community and Supportive Oncology. 15(1). e294–e296. 3 indexed citations

Lartigue, Jane De. (2017). Abemaciclib becomes first CDK inhibitor to clinch single-agent approval for breast cancer. The Journal of Community and Supportive Oncology. 15(6). 2 indexed citations

Lartigue, Jane De. (2017). Liquid gold: Blood-based biopsies make headway. The Journal of Community and Supportive Oncology. 15(1). 49–54. 2 indexed citations

Lartigue, Jane De. (2017). Hallmark tumor metabolism becomes a validated therapeutic target. The Journal of Community and Supportive Oncology. 15(6). e47–e52. 4 indexed citations

Lartigue, Jane De. (2016). Evolving therapeutic strategies maintain clinical momentum in melanoma. The Journal of Community and Supportive Oncology. 14(6). 280–286. 1 indexed citations

Lartigue, Jane De. (2015). Lenvatinib for advanced differentiated thyroid cancer. The Journal of Community and Supportive Oncology. 13(7). 237–239. 1 indexed citations

Lartigue, Jane De. (2015). Rising to the therapeutic challenge of head and neck cancer. The Journal of Community and Supportive Oncology. 13(2). 73–80. 2 indexed citations

10.

Lartigue, Jane De. (2014). Oral treprostinil for the treatment of pulmonary hypertension. Drugs of today. 50(8). 557–557. 7 indexed citations

11.

Lartigue, Jane De. (2014). Flutemetamol (18F): A beta-amyloid positron emission tomographytracer for Alzheimer's and dementia diagnosis. Drugs of today. 50(3). 219–219. 10 indexed citations

12.

Lartigue, Jane De. (2014). Moving beyond the one-size-fits-all formula for breast cancer treatments. The Journal of Community and Supportive Oncology. 12(8). 301–307. 2 indexed citations

13.

Lartigue, Jane De. (2012). Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma. Drugs of today. 48(10). 655–655. 6 indexed citations

14.

Lartigue, Jane De. (2012). Tofacitinib for the treatment of moderate to severe rheumatoidarthritis. Drugs of today. 48(8). 533–533. 2 indexed citations

15.

Lartigue, Jane De. (2012). Tafamidis for transthyretin amyloidosis. Drugs of today. 48(5). 331–331. 9 indexed citations

16.

Lartigue, Jane De. (2011). Corifollitropin alfa: A new option to treat female infertility. Drugs of today. 47(8). 583–583. 8 indexed citations

17.

Lartigue, Jane De, Ingrid Brust‐Mascher, & Jonathan M. Scholey. (2011). Anaphase B spindle dynamics in Drosophila S2 cells: Comparison with embryo spindles. Cell Division. 6(1). 8–8. 13 indexed citations

18.

Polson, Hannah E.J., Jane De Lartigue, Daniel J. Rigden, et al.. (2010). Mammalian Atg18 (WIPI2) localizes to omegasome-anchored phagophores and positively regulates LC3 lipidation. Autophagy. 6(4). 506–522. 543 indexed citations breakdown →

19.

Lartigue, Jane De, Hannah E.J. Polson, Kevan M. Shokat, et al.. (2009). PIKfyve Regulation of Endosome‐Linked Pathways. Traffic. 10(7). 883–893. 166 indexed citations

20.

Clague, Michael J., Sylvie Urbé, & Jane De Lartigue. (2008). Phosphoinositides and the endocytic pathway. Experimental Cell Research. 315(9). 1627–1631. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact